| Date | Title | Description |
| 18.08.2026 | Body Vision Medical Closes New Funding Round to Accelerate Global Expansion of AI-Powered Intraoperative Imaging | - |
| 08.07.2026 | Inside the NHS Hospital Trialling Psychedelics to Treat Depression | - |
| 15.05.2026 | EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder | The NiNA System® is not approved for sale or commercial use in the United States, Canada or Australia.
The Nina System® is a registered trademark of EBT Medical, Inc. in Canada.
About EBT Medical, Inc.EBT Medical is the originator and licen... |
| 29.04.2026 | Hope for Dry AMD: Novel Gene Therapy Completes First Human Safety Trial | Targeting Iron: A Novel Mechanism of Action
PST-611 sidesteps the complement pathway entirely, instead targeting a different biological process increasingly understood to be a key driver of retinal cell death in dry AMD: iron overload. Rese... |
| 11.02.2026 | ObvioGo Now Integrated with Oracle Life Sciences Clinical One Data Collection | Collaboration adds critical decentralized trial capabilities to the Oracle Life Sciences Clinical One Data Collection solution
NEW YORK, Feb. 10, 2026 /PRNewswire/ — ObvioHealth and Oracle Health and Life Sciences today announced that Obvio... |
| 22.01.2026 | Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) | - |
| 21.01.2026 | ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate | Next-generation therapeutic vaccines company also welcomes industry veteran Eric Halioua to board, as executive chairman. Lead candidate ErVac01 is a cancer vaccine targeting novel tumor antigens derived from human endogenous retroviruses.
... |
| 09.01.2026 | KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer | Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable colorectal cancer (MSS-CRC)
Company closed $22M financing to support randomized Phase 2b trial; IND cleared and s... |
| 29.10.2025 | Lattice Medical raises €43 million to transform post-cancer reconstruction | Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, announces a Series B fundraising round of €43 million, one of the largest of the year in the French Medtech sector. This major m... |
| 27.08.2025 | TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer | LONDON, Aug. 27, 2025 (GLOBE NEWSWIRE) — TREOS Bio Ltd., a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, today announced the execution of clinical collaboration agreements with... |
| 25.08.2025 | Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology | BRISBANE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) — Vaxxas Pty Ltd, the biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, today announced that it has secured ~$90 million in its ... |
| 20.05.2025 | Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis | - |
| 30.04.2025 | Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform | - |
| 16.04.2025 | Cadwell Makes a Strategic Investment in Seer Medical to Expand Home-Based Epilepsy Diagnostics | KENNEWICK, Wash., April 15, 2025 /PRNewswire/ — Cadwell Industries, Inc., a global leader in neurodiagnostic, neuromonitoring, and sleep solutions, today announced its strategic investment in Seer Medical, a Melbourne, Australia-based compa... |
| 11.03.2025 | SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing | SINGAPORE and NEW YORK, March 10, 2025 /PRNewswire/ — SPRIM Global Investments (“SGI”), a global investment firm specializing in clinical-stage life sciences and pharma services based in Singapore, and One Investment Management (“OneIM”), a... |
| 13.02.2025 | PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD | PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its S... |
| 17.01.2025 | ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation | AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management
NEW YORK, Jan. 14, 2025 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, today announced the ... |
| 09.01.2025 | RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases | Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity
Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a one-time, curative treatment
AURORA, CO, Janua... |
| 05.12.2024 | Cilcare completes a €40M series A | Montpellier, December 4, 2024 – Cilcare, a biotechnology company specializing in auditory sciences, today announced the closing of its €40 million Series A funding round, including €21 million raised during the latest round. This fundraisin... |
| 25.11.2024 | Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies | CHAPEL HILL, NC / ACCESSWIRE / November 25, 2024 / Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial S... |
| 19.11.2024 | Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe” | Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar’s novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases
SAN FRANCISCO, CA / ACCESSWIRE / November 19, ... |
| 16.10.2024 | ObvioHealth Welcomes Richard Watkins as Chief Revenue Officer at a Pivotal Moment of Transformation | Experienced Sales Leader to Drive Revenue Growth as ObvioHealth Transitions to Enterprise Solutions
NEW YORK, Oct. 16, 2024 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, announces the appointment of Richar... |
| 10.10.2024 | ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors | NEW YORK, Oct. 10, 2024 /PRNewswire/ — ObvioHealth, a leading digital health company revolutionizing clinical trial solutions, is pleased to announce the appointment of Nicholas Campbell to its Board of Directors. Nicholas brings over 20 ye... |
| 07.10.2024 | PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024 | PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be pr... |
| 24.09.2024 | SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites | September 24, 2024, SPRIM PRO – SPRIM PRO, a CRO renowned for its innovative approach to clinical trials and healthcare, is excited to announce its accepted, peer reviewed publication in Frontiers in Pediatrics medical journal entitled, “As... |
| 29.07.2024 | ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally | July 25, 2024 – (PRNewswire) – ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the can... |
| 24.06.2024 | Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment | June 18, 2024 – (Forbes Australia) – Founder and CEO Mimi Tang has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen and turn to the EpiPen in ... |
| 16.01.2024 | Stalicla Secures $17.4 Million in Series B Financing | - |
| 16.01.2024 | Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments | Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial
Source: Prota Therapeutics
Sectors: BioTech |
| 02.11.2023 | RegASK Welcomes New Chief Product & Technology Officer | NEW YORK and SINGAPORE, Nov. 2, 2023 — RegASK, a global regtech SaaS platform that enables businesses to leverage AI to scale their regulatory and compliance capabilities, announces the appointment of Amenallah (Amen) Reghimi as its new Chi... |
| 17.10.2023 | ObvioHealth Strengthens Leadership Team with Key Industry Appointments | - |
| 10.10.2023 | Fibronostics Announces Partnership with Stone Diagnostics | - |
| 29.09.2023 | Spexis provides business update and announces financial results for the first half of 2023 | Ad hoc announcement pursuant to Art. 53 LR
ALLSCHWIL, Switzerland, Sept. 28, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today... |
| 14.08.2023 | Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies | ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD ... |
| 14.07.2023 | Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight | - |
| 26.05.2023 | SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd. | - |
| 03.05.2023 | ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers | - |
| 18.04.2023 | Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study | Ad hoc announcement pursuant to Art. 53 LR
ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company ... |
| 06.04.2023 | AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates | AUM Biosciences, a Singapore-headquartered biotech company focused on precision oncology therapeutics, allotted shares worth $11.8 million earlier this week.
Everlife Holdings, a market access and distribution company in India and Southeas... |
| 28.03.2023 | 1nHealth Launches Site Advisory Board to Prioritize Site Voice | ORLANDO, Fla., March 28, 2023 (Newswire.com) – Today, 1nHealth launched its Site Advisory Board, a consortium of research site owner-operators brought together to advise 1nHealth’s recruitment efforts and technology development. The board w... |
| 27.03.2023 | STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD | STALICLA and Firefly Neuroscience enterPartnership Agreement for the Development of Electroencephalogram (EEG) asa Biomarker for Subgroups of Patients with ASD
Geneva, Switzerland – 27March2023, STALICLA S.A. and Firefly Neuroscience today... |
| 16.03.2023 | ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine | NEW YORK, March 16, 2023 /PRNewswire/ — ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines. The randomized controlled tri... |
| 09.02.2023 | Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A. | This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million
Jaguar currently owns approximately 73.5% of Napo Therape... |
| 08.02.2023 | Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin® | ALLSCHWIL, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company has executed term sheets describing a clinica... |
| 09.01.2023 | STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment | PRESS RELEASE
Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, today announced that it has entered into ... |
| 15.12.2022 | RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth | SINGAPORE, Dec. 15, 2022 /PRNewswire/ — RegASK, a global RegTech SaaS company, today announced it has raised a $10m Series A funding round. The round is led by venture capital firm Monograph Capital and joined by SPRIM Global Investments an... |
| 20.10.2022 | AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V | SINGAPORE and NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer... |
| 12.10.2022 | Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01 | - |
| 18.08.2022 | AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene | SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) — AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Admin... |
| 16.08.2022 | ObvioHealth Ranked on Inc. 5000’s List of Fastest Growing Private Companies for Second Consecutive Year | NEW YORK, Aug. 16, 2022 /PRNewswire/ — ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces today its inclusion in Inc. Magazine’s annual list of the natio... |
| 27.06.2022 | Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer | LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient ... |
| 15.06.2022 | Fibronostics Secures Financing, Announces New CEO | NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichw... |
| 02.04.2022 | LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients. |
This final part of the video informative series focuses on LIVERFASt, a non-invasive AI driven technology that helps provide quantitative assessments of lesions (fibrosis, steatosis, inflammatory activity).
Dr Mona Munteanu, the Fibronos... |
| 05.03.2022 | Faster, safer, more accurate trials. | ObvioHealth is pioneering new ways to collect clinical trial data. Their innovative platform seamlessly integrates with clinical-grade devices, their novel instruments reduce ePRO subjectivity, and their virtual study coordinators carefully... |
| 08.02.2022 | SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy | SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to the business, boost... |
| 08.12.2021 | The Digital Health 150: The Top Digital Health Companies Of 2021 | CB Insights has unveiled the third annual Digital Health 150 — a list of 150 of the top private companies using digital technology to transform healthcare.
The 2021 Digital Health 150 cohort has raised approximately $14.9B in aggregate fun... |
| 16.11.2021 | GHO Capital Acquires Genesis Research, a Pioneer in Tech-enabled Real-World Evidence and HEOR Services | - |
| 12.10.2021 | AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies | SINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging w... |
| 14.09.2021 | ObjectiveGI Announces Name Change to ObjectiveHealth | - |
| 01.07.2021 | ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally |
NEW YORK –July 1, 2021 – ObvioHealth, a global Virtual Research Organization(VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT ... |
| 07.06.2021 | ObvioHealth Announces a Groundbreaking Partnership with Dedalus Group to Unite Real World & Clinical Trial Data |
NEW YORK – June 7, 2021 – ObvioHealth, a global virtual research organization (VRO), is bringing clinical trial data fully into the continuum of care through a new strategic partnership with Dedalus Group, the leading healthcare and dia... |
| 01.03.2021 | Leveraging Next-Gen Tools in Rare Disease Research | The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are over 6,000 rare diseases global... |
| 07.01.2021 | Genesis Research Announces Acquisition of Evid Science | HOBOKEN, N.J. (PRWEB) JANUARY 07, 2021
Genesis Research LLC (GR), a Value Demonstration Company providing Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services to the health and life sciences industries, anno... |
| 24.08.2020 | Fibronostics Raises $8 Million in Series A Financing | - |
| 05.08.2020 | Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors | - |
| 23.06.2020 | The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training | The FDA recently released new guidance on drug development for the prevention and treatment of COVID-19, emphasizing the need for flexible trial designs, diverse patient populations and mechanisms to ensure data accuracy.
Digital component... |
| 18.06.2020 | ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients | - |
| 11.06.2020 | Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million | - |
| 08.06.2020 | SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD | - |
| 20.05.2020 | ObvioHealth Secures $17 Million in Latest Investment Round | - |
| 12.05.2020 | Travecta Therapeutics Secures $15 Million in Financing | - |
| 10.02.2020 | Ventures Day Singapore 2020: Post-event highlights | Following our three successful past events – June 2017 & January 2019 in Singapore and April 2019 in New York – SPRIM held another exciting Ventures Day at our brand new auditorium in Singapore.
Our CEOs, science/tech experts, and stra... |
| 07.06.2019 | AC Health Announces Investment in Fibronostics | Ayala Healthcare Holdings, through its technology arm, Vigos, expanded its digital portfolio with a recent investment in SPRIM’s sister company, Fibronostics. The agreement was signed by AC Health President and CEO, Paolo Borromeo, AC Healt... |
| 21.03.2019 | SPRIM’s Quarterly Ventures Day Meeting in New York | SPRIM, in partnership with Tikehau Capital, is hosting its quarterly Ventures Day meeting on April 24, and for the first time, the event will take place in New York.
This one-day meeting will provide unique insights into trends in biotech ... |
| 29.01.2019 | Objective GI Funding Announcement |
The clinical research company establishes partnerships with gastroenterology practices and is forecasted to grow to more than 30 research sites across the U.S.
NASHVILLE, Tenn. – January 29, 2019 – Objective GI, a gastrointestinal-focuse... |
| 28.01.2019 | TKS 1 Investor Day 2019 in Singapore: Post Event Highlights | Following a successful Ventures Day in 2017, we are back with yet another great event organized in collaboration with Tikehau Capital. This year’s event was held on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore where we w... |
| 15.01.2019 | RegASK, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth | RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy
SINGAPORE, January 15, 2019 – RegAsk, a company that uses artificial ... |
| 15.11.2018 | Evid Science Receives Seed Capital to Advance Clinical AI Platform | LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science c... |
| 15.11.2018 | SPRIM and Tikehau Capital Join Forces with New Singapore-based Life Sciences VC Fund | LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to lau... |
| 23.03.2018 | ObvioHealth Raises $3 Million in Series A Funding | OBVIOHEALTH, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding.
The financing round, led by TKS I, a life science and healthcare focused ven... |
